Test Price
2,800 AED✅ Home Collection Available
DLX3 Gene Trichodentoosseous Syndrome NGS Genetic Test in UAE – 2,800 AED
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing for single nucleotide variants and small indels in the DLX3 gene.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Hospital-grade sample integrity maintained throughout transport.
- ✓ Clinical Guidance: Telephonic post-test consultation with a Consultant Medical Geneticist for result interpretation and family risk assessment.
- ✓ Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Price: 2,800 AED | Turnaround: 3–4 Weeks | Sample: Peripheral Whole Blood or FTA Card Spot | Methodology: Next‑Generation Sequencing (Illumina NovaSeq X, 100× mean depth)
Test Overview & Methodology
The DLX3 Gene Trichodentoosseous Syndrome NGS Genetic Test delivers definitive molecular diagnosis by sequencing the entire coding region of the DLX3 gene with >99.9% nucleotide accuracy, enabling precise identification of pathogenic variants responsible for this rare autosomal dominant ectodermal dysplasia. This comprehensive analysis detects single nucleotide variants, small insertions, and small deletions across all exons and intron-exon boundaries, providing a complete genetic picture for individuals presenting with kinked or brittle hair, dental anomalies such as taurodontism and enamel defects, and increased bone density characteristic of trichodentoosseous (TDO) syndrome.
| Feature | Our Test (NGS Diagnostic) | Closest Alternative (Single-Gene Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% nucleotide accuracy, full gene coverage including all exons and flanking regions | 99.0% limited to selected exons only |
| Methodology | Next‑Generation Sequencing (Illumina NovaSeq X, 100× mean depth) with orthogonal confirmation | Capillary electrophoresis – slower, less comprehensive, higher per-base error rate |
| Speed | 3–4 weeks | 6–8 weeks |
| Clinical Report | Full variant interpretation per ACMG guidelines, pedigree analysis, and family risk stratification | Basic mutation call without comprehensive annotation or segregation analysis |
| Regulatory Compliance | DHA/MOHAP licensed, ISO 9001:2015 certified, UAE PDPL compliant | Limited to international accreditation only, lacking local regulatory oversight |
Physician Insight & Safety Protocols
“A genetic test result is one chapter in your health story, not the entire book. The DLX3 analysis must be interpreted within the full context of your clinical presentation, family pedigree, and a structured genetic counselling session. A pathogenic variant does not guarantee phenotypic expression, and a negative result does not exclude all possible genetic aetiologies. Always pair molecular data with comprehensive clinical evaluation before making medical decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Safety Advisory
Do not discontinue or alter any prescribed medication without explicit instruction from your treating physician. Genetic testing does not modify your current treatment regimen and should never be used as a sole basis for therapeutic changes.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Acute febrile illness at time of collection, recent blood transfusion within the past 4 weeks, or ongoing anticoagulant therapy that cannot be safely paused under medical supervision.
- Emergency Red Flags: Persistent bleeding at the venipuncture site lasting more than 10 minutes; sudden onset of dizziness, lightheadedness, or syncope; local signs of infection such as spreading redness, swelling, or warmth; any systemic allergic reaction including urticaria, angioedema, or dyspnoea. Seek immediate emergency medical attention if any of these occur.
Patient FAQ & Clinical Guidance
1. What is the DLX3 Gene Trichodentoosseous Syndrome NGS Test and who should consider it?
This advanced genetic test sequences the entire DLX3 gene to detect mutations responsible for trichodentoosseous syndrome, a rare autosomal dominant ectodermal dysplasia affecting hair, teeth, and bone. The test is recommended for individuals displaying clinical features such as kinked or brittle hair, dental anomalies including taurodontism and enamel hypoplasia, and radiographically confirmed increased bone density. It is also offered to at‑risk first-degree relatives for carrier confirmation and to guide reproductive planning decisions.
2. How is the sample collected and what are the pre-test requirements?
Sample collection requires a peripheral whole blood draw (two EDTA tubes, 5–10 mL total) or a dried blood spot on an FTA card. No fasting or medication cessation is required. Pre-test genetic counselling is mandatory to construct a three‑generation pedigree and document the family history of TDO‑associated features, ensuring accurate variant interpretation. For patients unable to visit the laboratory, our VIP Mobile Phlebotomy service performs collection at your home between 8 AM and 11 PM daily.
3. How accurate are the results and what happens after I receive my report?
Our ISO 9001:2015 certified NGS methodology delivers 99.9% diagnostic sensitivity for single nucleotide variants and small insertion/deletion mutations in the DLX3 gene, with all pathogenic and likely pathogenic findings confirmed by orthogonal Sanger sequencing. After result release, you will receive a telephonic consultation with our Consultant Medical Geneticist who explains the clinical significance of the findings, discusses implications for family members, and coordinates referrals to dermatology, dentistry, or orthopaedics through our integrated care network as clinically indicated.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All genetic data is encrypted, stored on UAE‑based servers, and processed solely under explicit patient consent with strict access controls.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Electronic health records and genomic data systems comply with mandated security and interoperability standards for health data exchange.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical testing and patient consent procedures adhere to the legal framework governing medical professional responsibility and patient safety.
- ISO 9001:2015 Certified: Certificate No. INT/EGQ/2509DA/3139 ensures robust quality management across all pre‑analytical, analytical, and post‑analytical laboratory processes.
- DHA Facility License No. 1143: Fully authorised by the Dubai Health Authority for genetic diagnostic services within Dubai Healthcare City.
Clinical & Logistical Metadata
| Test Name | DLX3 Gene Trichodentoosseous Syndrome NGS Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (2 EDTA tubes, 5–10 mL) or FTA Card Dried Blood Spot |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina NovaSeq X Platform, 100× Mean Depth with Orthogonal Confirmation |
| ICD-10-CM Code | Q87.8 |
| LOINC Code | 21637-8 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians